Sollers College

Tag: Careers in Healthcare

  • Evaluation and Detection of Signals in Pharmacovigilance

    Evaluation and Detection of Signals in Pharmacovigilance

    • Pharmacovigilance is the science of recognizing, assessing, comprehending, and preventing hazardous drug reactions.
    • The main objectives of pharmacovigilance are identifying and assessing previously reported adverse drug reactions; assessing previously reported adverse drug reactions, and lowering mortality and morbidity associated with adverse events.
    • PV, also known as post-marketing surveillance, is mostly done throughout the drug development phase.
    •  The most crucial part of pharmacovigilance is signal identification and evaluation.
    • A signal, according to the WHO, is reported information on a potential causal association between an adverse event and medicine, of which the association is undetermined. Frequently, a signal is represented by a small set of reports.
    • Signal identification and evaluation are crucial and intricate procedures. As a result, qualitative signal detection and assessment techniques utilized in pharmacovigilance.

    An Analysis of Signals

    The pharmaceutical industry and regulators are all very interested in the early detection of safety information as soon as feasible. Both qualitative and quantitative components make up signals.

    Different approaches for detection are required for different categories of adverse events. Early signal detection is the main purpose of pharmacovigilance. However, procedures for reporting spontaneous events have been created and are now utilized globally.

    Case-control, cohort, and spontaneous reporting are only a few of the sources that produce safety signals.

    Automatic Reporting System

    • Most of the current pharmacovigilance relies on a spontaneous reporting mechanism. The spontaneous reporting system often includes case reports and case series. Early detection of signals from new, uncommon, and severe ADRs is the primary purpose of SRS.
    • A medically qualified person reports an incident voluntarily to a drug information center, where the reports are analyzed. Spontaneous reports are used to keep track of the underreporting of adverse medication responses and quality deviations. Underreporting is the main reason for the public’s lack of understanding among health professionals and the public.
    • Another issue in this system is selective reporting, which can create the perception of a risk when there isn’t truly one. Therefore, even though spontaneous reporting is inexpensive, it is not the ideal solution for postmarketing drug surveillance.
    • Nevertheless, we cannot dispute the fact that spontaneous reporting was and continues to be the primary method of identifying early drug safety signals. As evidence of SRS’s effectiveness in identifying fresh safety signals, most pharmaceutical goods are pulled off the market on its premise. 

    Recurrent Safety Update Report

    • The PSUR can be a valuable resource to find novelty signals. The purpose of a PSUR is to inform the competent authorities at specific intervals after permission of an update on the global safety experience of a medical product.
    • PSURs must be submitted for all registered products, no matter how the product is marketed. One report may be used to cover all items authorized by one marketing authorization holder that contains the same active ingredient.

    Trigger Tools Are Used to Produce Signals

    • Healthcare professionals are looking for an accurate and trustworthy technique for measuring and identifying adverse drug reactions in hospitalized patients.
    • The clinical pharmacist monitors the efficiency of drugs using electronic systems and is responsible for identifying early adverse drug reactions and other drug-related issues.

    Examination of Signals

    • Multiple criteria are used to assess signals. Before considering a report of a brand-new adverse drug reaction, high-quality report facts must be there.
    • Numerous tools are used to create high-quality data, including various applications and techniques. 
    • Additionally, a few studies have been published to demonstrate the relationship between cause and effect, but regrettably, there is no widely accepted method for identifying the cause of ADRs.

    Quality Control

    • Signals having insufficient information might render determining an event’s cause unfeasible. The information on patients and medications is the essential foundation for the subjective evaluation of the quality of the reports.

    The strength of the adverse event

    • The incident’s description and the data provided in the pertinent section of the ADR forms are used to determine how serious the event is.
    • Adverse occurrences are considered serious if they were fatal, life-threatening, resulted in significant impairment or incapacitation, or required extended hospitalization.

    System for Reporting Adverse Events

    • The FDA’s Adverse Event Reporting System is a database that contains information on reports of drug mistakes and adverse events. The FDA’s post-marketing safety surveillance program for pharmaceutical and therapeutic biologic products is supported by the database.
    • Adverse events and medication errors are classified by Med DRA nomenclature.
    • The AERS can be used by the FDA to perform duties like looking for recent safety concerns that might be related to commercially available products and evaluating a manufacturer’s compliance with reporting requirements.

    The Argus Safety Database

    • One of the most important components of the pharmacovigilance software system is the Argus Safety 3.0.1 database. Employers can use the digital database to support pharmacovigilance and other relevant operations while ensuring compliance with international laws.
    • It provides a pharmacovigilance business process that occurs during the drug’s pre-and post-marketing phases as a full pharmaceutical software solution. The Argus database is housed in an ISO-9001 accredited data center that complies with the safety regulations set forth by the FDA regulations.
    • Oracle Argus Safety products that are related to Oracle Argus Safety include Oracle Argus Insight, Oracle Argus Perceptive, Oracle Argus Affiliate, Oracle Argus Dossier, Oracle Argus Interchange, Oracle Argus Reconciliation, and Oracle Argus Unblinding.

    Recent Advances in Methodologies

    • Risk management plans have recently been established in post-marketing surveillance to systematically characterize, prevent, or limit hazards associated with pharmaceutical products, including the evaluation of the intervention’s efficacy.
    • The benefits-risks of the medicine throughout the post-authorization phase can be better comprehended with the aid of these RMPs.
    • To effectively identify the warning signs of adverse events, health professionals must present accurate information in their adverse event reports. The quality of adverse event reports is improving as more reports are made online.
    • Another crucial breakthrough is patients’ taking part in pharmacovigilance. Patients can now report ADRs to the spontaneous reporting system in many nations. Data can be collected and analyzed quickly with this kind of automation.

    Further Outlooks

    • Academics must create fresh approaches that can improve the current system to further demonstrate pharmacovigilance’s scientific validity. Active observation is required to learn about the drug’s safety at an early stage.
    • One must keep the significance of being able to obtain information promptly in mind when creating new techniques for active post-marketing surveillance. In most cases, the techniques, and the results conflict. Therefore, it’s critical to provide techniques for answering this kind of query.
    • Patients’ roles are progressively evolving. The patient is now well-informed about his illness and eager to take an active role in his care. Therefore, in the future, pharmacovigilance must focus on this group as a key source of information.
    •  Future pharmacovigilance must be capable of quickly recognizing novel safety signals. If this is successful, the patient’s faith in medications will return.

    The scope of the research

    • The most crucial part of pharmacovigilance is accurate signal identification and assessment. Signal detection is accomplished using a variety of techniques. Pharmacovigilance signals come from a variety of sources. 
    • PV may not be dependent on a single technique but rather on a coordinated set of actions. Through effective training and retraining of the staff involved in the pharmacovigilance activity, the quality of the reports can be enhanced. 
    • No single causality assessment technique is accepted by everyone. Therefore, the current desire is for a single effective strategy that is accepted by everyone.

    Sollers College will help you bridge the gap between these lucrative jobs and the skills required by prospective candidates. A career in pharmacovigilance affords you the chance to make a difference in people’s lives due to the current increase in the need for pharmaceutical specialists.

  • A validation study of intelligent automation for pharmacovigilance

    A validation study of intelligent automation for pharmacovigilance

    Pharmacovigilance is the discipline of keeping an eye on the effects of pharmaceuticals to spot and assess potential side effects and provide necessary and prompt risk reduction measures.

    Automating regular tasks and balancing resource consumption across safety risk monitoring and other pharmacovigilance operations are both possible with intelligent automation technology. New technologies like artificial intelligence (AI) hold enormous promise for improving pharmacovigilance because of their capacity to learn from data inputs.

    However, existing validation criteria should be supplemented to test intelligent automation systems. While the fundamental requirements for validation generally stay the same, new tasks designed for intelligent automation are required to provide proof that the system is fit for its intended use.

    The validation of AI-based systems

     There are three types of intelligent automation systems, ranging from rule-based to dynamic AI-based, and each type requires a different validation strategy.

    By building on current best practices for automated production, a risk-based strategy for artificially intelligent static systems is presented. Assistive technology solutions can be developed, applied, validated, and maintained by pharmacovigilance experts using framework. 

    • A successful pharmacovigilance expert must bridge the gap between business operations and technological innovation to prepare for inspections and comply with international regulatory agencies.
    • A significant number of resources is devoted by pharmacovigilance departments to processing adverse event (AE) cases, and according to benchmark data, the number of AE cases is rising.
    • Automating routine tasks and balancing resource use across safety risk management and other pharmacovigilance activities are both possible with intelligent automation technologies. 
    • Intelligent automation can improve the accuracy and reliability of case processing and evaluation, enabling a prompt evaluation of safety signals. 
    • The use of such technological solutions to assist with AE cases must be validated in accordance with regulations.
    • Automating regular tasks and balancing resource consumption across safety risk monitoring and other pharmacovigilance operations are both possible with intelligent automation technology. 
    • Intelligent automation can enhance the accuracy and reliability of case processing and evaluation, enabling a prompt evaluation of safety warnings. When such technological solutions are used to assist in the handling of AE cases, pharmaceutical firms must validate this software in accordance with laws. 
    • Computerized system validation (CSV) is the procedure used to confirm and record that the requirements for a computerized system are continuously met from the time of design until its decommissioning and/or transfer to a new system. 
    • The method to be used for validation should be centred on a risk assessment that considers the system’s intended usage, the possibility that it could have an impact on human subject protection, and the dependability of trial outcomes. 
    • For many years pharmacovigilance has made extensive use of algorithms, rule-based software, computerized workflows, and pattern matching. Robotic process automation has been used by several businesses and suppliers more recently to help manage individual case safety reports.
    • Machine learning (ML) and natural language processing (NLP) approaches are two recent fields of research based on artificial intelligence (AI) technologies that are currently being used to support pharmacovigilance procedures. 
    • The potential of this kind of technology to learn from data inputs offers enormous promise, but to validate intelligent automation systems, already-existing validation frameworks may need to be strengthened. 
    • For the system to meet its intended uses, it is necessary to perform more software development activities specifically geared toward intelligent automation.

    Graduate Certificate in Training in Drug Safety and Pharmacovigilance

    An innovative course created for professionals seeking a career in drug safety that makes use of the in-demand, business-based Oracle Argus Safety Database Software. 

    Invest in pharmacovigilance to start your path to a rewarding career. Learn how to launch your PV project successfully.

  • Pharmacovigilance and Drug Safety: Market Trends and Forecasts

    Pharmacovigilance and Drug Safety: Market Trends and Forecasts

    Market size and analysis for drug safety products and pharmacovigilance

    The market for drug safety solutions and pharmacovigilance is primarily driven by the increase in adverse drug reactions, which are becoming more common. 

    Additionally, the strict government rules for drug pre- and post-commercialization and outsourcing firms’ growing use of pharmacovigilance software contribute to the market’s overall expansion. 

    The market is anticipated to gain from research partnerships and collaborations that help to achieve more effective and long-lasting mechanical hemostasis, as well as from drug safety solutions and pharmacovigilance automation.

    Data Bridge Market Research projects that the market for drug safety solutions and pharmacovigilance, which was valued at USD 7.8 billion in 2022, will increase to USD 13.91 billion by 2030, with a CAGR of 7.50% from 2023 to 2030. 

    The market reports created by Data Bridge Market Research include in-depth expert opinions, patient biostatistics, pipeline evaluation, pricing analysis, and regulatory framework in addition to perspectives on market situations like market price, growth rate, segmentation, geographic scope, and big players.

    Market Size for Drug Safety Solutions and Pharmacovigilance

    • Pharmacovigilance (PV or PHV) is the process of collecting, analyzing, monitoring, and preventing adverse effects in drugs and therapies. 
    • Its primary goal is to ensure that pharmaceutical developers meet industry regulatory standards, and it puts additional pressure on biotechnology and pharmaceutical companies to manufacture safe drugs and evaluate their post-sale results.

    Market drivers for drug safety products and pharmacovigilance

    Increased regulatory requirements for drug development

    • The demand for PV services is being driven by regulatory requirements for conducting clinical trials and post-marketing vigilance. For instance, the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) create regulatory guidelines for all phases of clinical trials. 
    • The ability to report accurate data, which research professionals can then use for prospective studies, has been made possible by advancements in the development of ADR databases and information systems, which have increased overall demand.

    Drivers of the drug safety and pharmacovigilance markets

    Higher standards for generating drugs

    • The rules governing how drug studies are conducted and post-marketing surveillance are what primarily drive demand for PV services.
    • ADR databases and information systems have improved overall demand, allowing research professionals to use accurate data..

    Restraints/Challenges

    Regulations relating to drug safety are becoming more complex.

    • Drug safety regulations are becoming more complex, as are misquotations and incorrect coding of adverse effects.
    • A comprehensive study of the drug safety solution and pharmacovigilance market discusses recent developments, trade regulations, import-export analyses, production analyses, value chain optimization, market share, and the impact of domestic and localized market participants. 
    • Besides analyzing potential revenues pockets, it also analyzes regulatory changes, market size, category market expansions, application niches, and product approvals. 

    Market Size for Global Drug Safety Solutions and Pharmacovigilance


    Pharmacovigilance and drug safety solutions are categorized based on their type, product, functionality, end user, delivery method, and distribution channel. It will be possible for you to identify key market applications by analyzing the industries’ scant growth segments and providing users with valuable market information and market insights.


    Type – Services and Software

    Products – The functionality of Standard Form and Customized Form 

    Functionality – Software for Drug Safety Audits, Adverse Event Reporting, and Issue Tracking

    Delivery: Mode of delivery to site

    Delivery Mode: On-Demand/Cloud-Based

    User Groups

    Pharmacology and life sciences

    Research Organizations Under Contract (CROS)

    Hospitals

    KPOs/BPOs

    Medical professionals

    Direct Selling

    In-Store Sales

    Distributing Route

    Regional Market Analysis and Insights for Drug Safety and Pharmacovigilance


    The drug safety solutions and pharmacovigilance market are analyzed, and market size insights and trends are presented by country, type, product, functionality, end user, delivery method, and distribution channel. 

    Indicators used to forecast a specific country’s market scenario include technical trends, Porter’s Five Forces analysis, case studies, and upstream and downstream value chain analysis.

     Forecasts also take into account the availability of international brands, their difficulty in competing with local or domestic brands, the effect of domestic tariffs, and trade routes, when analyzing country data.

    Growth of the healthcare infrastructure installed base and invasion of new technology

    In addition, the market for drug safety solutions and pharmacovigilance analyses the growth of healthcare capital equipment expenditures for each country in detail, as well as the installed base of various product types within the pharmacovigilance and drug safety solutions market. As well as the impact of technological advances such as lifeline curves, healthcare regulatory changes and their impact on pharmacovigilance and drug safety solutions.

    Market share analysis for the competitive environment, drug safety solutions, and PV

    The company’s financials, revenue generated, market potential, investment in R&D, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance are among the details that are included. The data points mentioned above only pertain to the companies’ focus on pharmacovigilance and drug safety solutions.

    Sollers carefully consider your needs before creating an all-encompassing plan from start to finish. Every student is capable of acquiring the skills and knowledge required for success. 

    Successfully launch your career. Utilize the chance you have to succeed in life and influence others.

    Making a difference in people’s lives is possible with a career in drug safety and pharmacovigilance. 

    This is a result of the recent rise in demand for experts in pharmaceuticals and drug safety.

    At Sollers College, the pharmacovigilance and safety programs are accredited.

  • A six-level framework for streamlining pharmacovigilance

    A six-level framework for streamlining pharmacovigilance

    To gather information about adverse events and address patient safety, pharmacovigilance is essential. The AE case processing segment, a crucial component of PV, currently faces many difficulties.

    Adverse event reporting is costly, time-consuming, and subject to human error, which could hurt patient safety. The industry will significantly benefit in the future from the promise of intelligent automation made possible by artificial intelligence and machine learning.

    Artificial intelligence (AI) and machine learning (ML) have the potential to revolutionize the sector through automation technologies.

    Level 0: The level of automation is not present

    Stage zero, or manual case processing, excludes any automation support. The entire case intake and processing process are fully manual, and the case submission process and any decision-making that results from it are entirely handled by human users. Intervention systems may improve this performance, but the execution of the process remains schematic.

    In terms of balancing compliance and cost, this may be all that is ever required for organizations with low volumes of adverse events. Several digital tools exist to automate steps in the process, which provide progression to the next stage.

    Level 1: This level of service is only for assistance

    Initially, autonomy can only help; human supervision is essential.

    For many years, PV has included this level of automation to varying degrees. Auto-narratives and letter generation are two examples of how proven tools transform structured case data by manually selecting from pre-defined templates that are set up to match company-specific nuances. Instead of investing time and resources in manually creating these free text summaries, these examples show how auto-narratives and letter creation work.

    Currently, most PV departments are automated with only minimal assistance.

    Level 2: Automate a portion of the process

    As automation advances, fewer scenarios call for manual intervention, though human users still monitor case processing and still intervene when necessary. In our analogy of an autonomous vehicle, automation enables the system to take over multiple tasks at once, such as steering, acceleration, and deceleration.

    For instance, automating data extraction and identification from source documents speeds up case processing; doing this work in advance improves the ability to identify follow-ups and reduces the need for multiple copies.

    Level 3: Automated systems that are conditional

    Another situation where AI can do work-intensive tasks is bulk literature screening. Smart algorithms can parse more content in less time with better accuracy than PV professionals could by reading peer-reviewed literature and reports for AE signals over hundreds of hours.

    Although there will be false positives requiring review, it is interesting to note that an automated PV system using natural language processing is more likely to find arbitrary mentions of ailments or products than a human reader. Alternatively, this can be done algorithmically, as it is when associated with null flavor values. 

    In either case, functionality reducing the need for human resource usage lowers the costs of pharmacovigilance, improves safety outcomes, and frees up PV professionals for more value-driven activities.

    Level 4: This is the level that represents a high degree of automation

    Due to its high level of automation, the system can handle each aspect of numerous case types. System quality and compliance are not always ensured by manual action, even when notified by human users.


    At this point, the system can carry out all the operations necessary to receive and register a case report. This includes validation, duplication checks, and data entry from compatible systems. Medical evaluations are possible for a wide range of case types, and ML is increasingly enabling QC.

    Following learned criteria, the triage function assigns cases a ranking for reporting purposes; a request for intervention is only made when a case deviates from the data’s assumptions. Depending on the health authority in question, the client risk profiles, and how well the case complies with other requirements, manual intervention may or may not be necessary when submitting to authorities or partner organizations. Depending on several factors, case closure and archiving can be automated.

    Level 5: level of complete automation of the process

    A PV system can execute autonomous case processes and submissions for all case types once it reaches full safety automation status. For any given case or report recipient, no manual intervention is necessary.

    When the process is fully automated, AI can act to reduce patient risk if the system sends an intervention request, but no human responds appropriately. The actions are pre-set and automated for safety reasons, whether that means launching a national alert about a drug-related adverse event or putting a hold on dispensing a batch.

    Positive effect on the economy

    The life sciences industry gains from autonomous case processing in several ways. The traditional case processing workflow can be turned on its head, and labor-intensive and expensive processes can be automated, saving organizations time and money.

    As a first step, companies need to assess their current situation and set precise goals in terms of PV automation. Risk tolerance should be considered when setting these goals. Even though there is no one-size-fits-all strategy, everyone should start small and introduce automation gradually as technology develops to the point where it can solve unimaginable problems.

                                                                                 Sollers partners with industry-leading employers in all fields.

    Sollers prepares a comprehensive plan from start to finish based on a detailed analysis of your needs. Students will gain both the background and skills they need to succeed at an affordable price.

                                                                                Get your career off to a successful start.

  • Is pharmacovigilance becoming more of a leadership role in health care?

    Is pharmacovigilance becoming more of a leadership role in health care?

    Pharmacovigilance provides numerous career advancement opportunities in the drug industry. The increased number of drugs and biologics entering the market, as well as the improved drug safety regulatory framework, has increased the demand for skilled resources to carry out PV activities. Because of increased drug safety awareness, rigorous yet cost-effective Pharmacovigilance systems and operations are required. 

    The PV market has recently seen rapid expansion. PV is now well-established as a science in the biopharmaceutical industry. As a result, PV outsourcing has gained traction, resulting in more job opportunities. 

    Both technical and interpersonal abilities are required for any aspiring PV professional. The individual should have a degree in life science, nursing, pharmacy, or a related field. A career in PV is as fulfilling as any other allied healthcare career because the work is so varied. Many pharmaceutical products are collected and analyzed for patient safety.

    PV regulations ensure patient safety in pharmaceutical development and marketing. The pharmacovigilance market demand for direct benefits to manage patient safety is actively growing.
    Hence, a career in Pharmacovigilance can be both rewarding and challenging.

     

    The Industry’s Core Pharmacovigilance Functions and Their Responsibilities

    Along with soft skills, PV is a specialty in the field that calls for specialized knowledge and abilities in pharmacology, PV information sources, critical analysis of biomedical literature, rules, systems, and procedures. 

    The operations typically start with case handling, where reports of adverse events and spontaneous drug reactions from clinical trials are gathered from a variety of sources, including investigation sites, medical staff, patients, publications in the literature, and regulatory agencies.

    Along with these tasks, the PV operations also involve developing and creating countermeasures and risk evaluation and mitigation strategies. The goal of these documents is to ensure the patients’ safety by giving clear instructions on the risks associated with using medications, monitoring them, and taking initiatives to reduce such risks.

    User activities with pharmacovigilance

    Besides its primary duties, the PV department is empowered by management and given support, clinical research, regulatory affairs, healthcare affairs, literature searches, information review, information technology, and assistance, quality assurance, project management, production processes, security of the supply chain, and marketing.

    Since a medical review of the safety data is essential before submission to health authorities, close cooperation between medical affairs and PV is essential. This guarantees that a suitable company comment is given to the ICSRs and that periodic safety reports are reviewed.

    The compliance and training group is another interface function that closely collaborates with PV. This group is crucial to the operation of a Pharmacovigilance system because it makes sure the business complies with all laws and regulations about its PV obligations as well as by giving human resources working in various PV functions the necessary training and exposure. 

    The compliance teams assist PV with quality assurance, including audits and inspections. Employees in the compliance and training groups must be knowledgeable in the field of PV.

    PV focuses on the pharmaceutical sector

    In the pharma sector, PV as a discipline is now well-established. When conducting PV activities, an organization must have access to a great deal of skilled, suitably qualified, and trained personnel to produce the desired quality results. This makes it easier to derive a meaningful conclusion from the data and then submit it in a predetermined format for reporting purposes.

    Pharmacovigilance: career-enhancing abilities

    For a PV career to be successful, it requires a mix of both soft skills and technical skills. Organizations have formed hiring strategies for various PV roles and responsibilities, and such plans necessitate that the candidates fulfill these prerequisites.

    With more roles, there are more requirements. The requirements can be broadly divided into three groups:

    1) Technical expertise

    Aspiring PV professionals must be familiar with the fundamentals of pharmaceuticals, healthcare, ADR, EU, and GPP. Although candidates with a life sciences degree can obtain an entry-level position in PV, there is generally a preference for healthcare professionals in the pharmaceutical industry. 

    Graduates in life sciences can apply for a PV position. Dentistry, nursing, pharmacy, and life sciences are among the academic specialties represented among the staff members of the current PV organizations. The PV organizations primarily hire graduates with healthcare degrees in medicine or pharmacy.

    2) Skillsets

    Along with the necessary technical skills, specific soft skills are crucial to one’s employability in the PV industry. Qualified candidates for any PV role must demonstrate skill competencies to support their technical knowledge during the interview process.

    1. Acquiring the necessary skills to advance your career

    A successful career progression also depends on ongoing learning and development while working, in addition to the technical and soft skills mentioned above. Professionals who possess these skills are better able to learn beyond the curriculum content and are constantly on the lookout for innovative concepts and cutting-edge technology. Through practice and self-motivation, these abilities are easily learned and acquired.

    Synopsis

    For graduates and postgraduates in medicine, pharmacy, and the life sciences, the industry currently offers a wide range of opportunities in PV. Because the work entails gathering and analyzing safety data for many medications aimed at patient safety, a career in PV is equally as fulfilling as any other allied healthcare career. 

    Candidates interested in pursuing careers in PV should be passionate about their work because it will have an impact on society. In the labor market, there will be a persistent need for qualified PV personnel.

    For successful career development, jobs in the industry would need both technical and soft skills. Once employed as a PV, there are many opportunities for career development through ongoing education and training.

     Pharma companies can take advantage of the opportunities. Continuous self-development is the key to career advancement in the PV sector.

     PV professionals should investigate opportunities for lateral and vertical growth, enrichment, realignment, and transition if they want to have a successful career in the sector.

     

    It is now possible at Sollers college to learn how to effectively master the fundamentals of action potential in just one place so that you can soar to ever-greater heights as you strive to reach ever-higher levels. 

    Create a pathway and learn in multiple ways and don’t hold yourself back. Boost your professional life by optimizing it and reaping the rewards!

  • What are the six most influential factors in pharmacovigilance?

    What are the six most influential factors in pharmacovigilance?

    The development of new pharmaceutical products is heavily reliant on pharmacovigilance. It guarantees that these goods are used safely and efficiently to improve patients’ health. Due to increasingly strict rules and the growing significance of patient-centricity, pharmacovigilance is now much more important than it was formerly. The industry’s current pharmacovigilance trends are outlined in detail.

    1. Driving efficiency and profitability through procuring

    Pharmacovigilance-specific outsourcing is becoming increasingly popular as a means of coping with the rising cost of keeping an internal workforce that is highly skilled and trained.

    An effective pharmacovigilance outsourcing program has measurable advantages for manufacturers and sponsors. Businesses nowadays outsource their pharmacovigilance work to improve regulatory compliance, quality, productivity, and strategic decisions. 

    1. Early assessment of safety concerns using qualitative and quantitative data 

    Secondary data sources have multiplied over the past few years and at this time includes:

    Social networking, computerized medical records, and claims files. Regulatory reports and documents filed by various authorities. 

    The gathering and integration of secondary data sources with traditional datasets present special difficulties. From a regulatory standpoint, pharmaceutical companies are now just at the beginning stages of their use of secondary data.

    However, initiatives like the Sentinel Initiative of the FDA and WEB-RADR of the EMA demonstrate the interest that regulatory bodies have in the utilization of secondary data.

    Technology vendors have recently begun to provide reliable and adaptable systems that aid life sciences organizations in handling and integrating a variety of file kinds and integrating social media streams into their pharmacovigilance operations.

    Social media streams are being added to the scope of sophisticated algorithms and disproportionality analysis, in addition to conventional spontaneous reporting.

    The combination of secondary data sources and cutting-edge signal detection technologies enables the quicker identification of safety issues and the implementation of risk reduction measures.

    1. Cloud-based Data to Create a Powerful Global Adverse Event Network 

    Massive volumes of data can now be stored and analyzed in the cloud, which is advantageous for many sectors. Life sciences organizations must optimize the intake, storage, and analysis of large volumes of data as the number of data sources increases.

    Moving to the cloud is primarily motivated by:

    Cost-effectiveness: Using the cloud may allow businesses to deal with a large volume of case data while maintaining quality, security, and data privacy. 

    Scalability: The volume of adverse event cases for life science firms has been increasing rapidly, with some firms reporting a yearly increase. This increase necessitates the use of equipment that can easily handle the growing volume of data.

    By letting firms avoid concerns about module compatibility and server scale, cloud utilization can make life simpler for them.

    1. Protection and assimilation of vast amounts of information using big data

    In recent times, pharmacovigilance specialists have gained access to new digital sources of experimental data and real-world evidence.

    Big data sources used in pharmacovigilance include:

    Signal identification; confirmation and substantiation of safety signals for drugs or vaccines; online channels and social media. 

    Because of its complexity, big data represents both a challenge and an opportunity. Life sciences firms employ big data to better effectively monitor and research drug safety thanks to technological advancements with high-end computer capabilities.

    1. Data Analytics to Drive Useful Understanding


    For a comprehensive knowledge of safety occurrences, it is essential to handle safety data collected across numerous platforms effectively. A rising number of life sciences organizations use cutting-edge pharmacovigilance techniques to analyze vast and diverse data sets, including safety information. To safeguard the safety of their patients more effectively, they work to identify novel patterns, unrecognized correlations, trends, and patient preferences.

    These days, pharmacovigilance analytics offers a real chance to successfully harness data, assure regulatory compliance, and generate useful insights.

    1. Streamlining Non-Value-Adding Activities in Pharmacovigilance Functions

    Companies in the life sciences industry are actively seeking solutions to cut down on the rising cost of pharmacovigilance and the likelihood of human mistakes in pharmacovigilance jobs. Automation is a key component that can assist companies in achieving both objectives by:

    Streamlining the entire safety procedure

    removing unnecessary steps from the existing procedure

    improving team productivity.

    Life sciences organizations have an increasing number of opportunities to incorporate automation into their routine pharmacovigilance activities as regulatory bodies roll out new tools to gather and analyze adverse occurrences.

    Sollers College will assist you at every step of the journey. We are your first point of contact for any support you may require. Sollers gives you any information you need about your career.

  • The Current Pharmacovigilance System Goals

    The Current Pharmacovigilance System Goals

    • Due to increased concerns about pharmacovigilance, PV has become more crucial in the pharmaceutical industry.
    •  PV, according to the World Health Organization, is the science and methods involved in the ongoing detection, evaluation, and comprehension of adverse events or adverse medication reactions to determine the risk profile of a product.
    •  A primary national regulatory authority and numerous regional or national centers make up the common structure for a national pharmacovigilance system.
    •  According to WHO, National Centers are pharmacovigilance facilities authorized by the organization that are in nations taking part in the WHO Programme for International Drug Monitoring.
    •  Typically, NCs are affiliated with or a component of the national drug regulatory body. Individual case safety reports are sent to a local PV center by healthcare professionals and patients.
    • The drug safety sector is currently under pressure from expanding data quantities and complexity to find solutions that lower case processing costs while maintaining compliance with globally changing standards and preserving or even improving the information quality in ICSRs
    • In parallel to this, regulatory organizations are pressuring doctors to record more instances of PV, and patients are also sharing their accounts of adverse events. 
    •  This entails making use of outsourcing partners’ advantages, which help manage workload demands and limit workforce expansion while delivering scalability. Although the opportunity for outsourcing is limited, the processing still requires manual labor.
    •  Pharmacovigilance is a post-marketing tool that guarantees a drug’s safety. The detection of ADRs and the mitigation of related hazards are its main concerns. Regarding tiers of the social healthcare setting, a well-structured PV system can assist in producing correct safety data.
    • A well-thought-out plan that guarantees flawless execution and tangible benefits is required for the establishment of a pharmacovigilance system.   

    Current Pharmacovigilance Challenges

    PV systems have come a long way over the past few decades, but they still face several obstacles today. A well-designed PV system can assist in accurately generating safety data for several spheres of the social healthcare setting. The establishment of a pharmacovigilance system necessitates the harmonization of several criteria and a carefully thought-out strategy that guarantees flawless execution and physical benefits.

    The Current Pharmacovigilance System Goals

    Situation 1: Inconsistent reporting of adverse events

    • Adverse events, however, do not always occur while visiting the healthcare center. It can happen several hours after the medicine was administered. Patients frequently struggle to appropriately report AEs since they can’t recall every detail about them.
    • When a patient disregards medical advice or experiences negative effects from drugs taken simultaneously with prescribed therapies, this is referred to as an adverse event. Such inaccurate reporting may cause drug safety committees to draw erroneous conclusions, which may result in the suspension or removal of medications.

    Situation 2: Constantly changing laws and business practices

    •   PV systems must scale easily and effectively because of business expansion into newer markets. It has become crucial to ensure that PV systems and procedures continue to advance.
    •   The underlying database, configurability, reporting capacity, and system connection with data sources and other applications are just a few areas where the evolving regulations have an impact on PV operations.
    • Regulation non-compliance and the resulting fines are caused by a lack of support and continually evolving standards. The need varies more widely in non-ICH regions, making reporting even more challenging.

    Situation 3: Data Processing and Detection

    • Because of the steadily increasing amounts of AE data, it is difficult for reviewers to track, identify, and manage all potential developing patterns using only qualitative methods. Since manual processes take a long time, it can take the reviewer a few weeks to study a particular signal.
    •   On the other hand, the regulators’ and life science enterprises’ query and response cycles are rapidly closing, forcing the reviewers to quickly assess the signals.
    • Reviewers must concentrate on current problems while spending less time and effort identifying false signals. Ineffective signal detection and handling make it difficult to meet regulatory reporting requirements, which results in fines.

    Situation 4: Operational efficiency and productivity

    • When transferring and submitting cases across ICH areas, an organization faces many challenges. Some businesses choose to send the submission data back to their main office to keep the central system up-to-date.
    • Routing and maintaining track of ICSRs must be done manually because pharmacovigilance is not automated. The procedure is delayed as a result, and AE processing and reporting are inadequate.

    Situation 5: System Implementation

    • Existing PV systems have problems with system integration, data sharing between unrelated applications, system availability, and system scalability. It leads to a system breakdown because of poor scaling and shaky performance.
    • Data inconsistency results from the manual intervention involved in this. As a result, productivity and efficiency suffer in PV departments.

    Situation 6: Handling a larger volume of data

    • v  Processing the growing amount of data that the ecosystem is producing is posing a serious issue for the worldwide PV business.
    • v  An annual exponential increase in data quantities is being caused by a variety of sources, including journals, publications, social media, patents, and an increasing number of unstandardized data sources.
    • v  However, many businesses continue to manage information using outdated technological platforms and manual procedures. This reduces productivity and is prone to mistakes.

    Situation 7: Ensuring Data Quality

    • The complexity and variety of the technologies used to gather and store the data are growing along with the volume and type of data being collected during the life cycle of the product.
    •  Certain data input and data coding standards are essential for accurate reports and signal detection.
    •  To maintain quality, newly entered or received data must be reviewed for quality.
    • A PV system should adhere to certain specific parameters to reduce errors in signal detection, recorded data, and aggregate reporting.

    ‍ Join Sollers College today to start your career in drug safety and pharmacovigilance. Your PV skills will be helped at every stage of the curriculum. Students who are ready to develop their profiles can choose from training programs offered by Sollers.

    Sollers’ College distinctive curriculum consistently creates a wide range of career options and offers the best professional supervision and swift learning support.

    To learn and share your knowledge, Sollers College created a road to the sizable pharmaceutical sector. Don’t let yourself be limited to meeting your needs in this pharmaceutical market.

  • Fundamental Updates on Pharmacovigilance-Technology, Analytics, and Automation

    Fundamental Updates on Pharmacovigilance-Technology, Analytics, and Automation

    Pharmacovigilance systems are now being changed by developments in health care, such as complicated international legislation, an increase in the volume of adverse effects, and new data sources. Analytics, automation, and cognitive technologies offer the potential to refocus the pharmacovigilance role from collecting and reporting data enhancing product quality, and treatment regimens, lowering costs, and enhancing patient safety.

    Outlook on the expanding pharmacovigilance

    • The pharmacovigilance function has overseen the gathering, processing, and informing regulators of adverse events and other product safety data for several decades. Because PV is a process-intensive technology, corporations frequently choose the safety systems that go with it based on how well they can organize data and maximize efficiency, which leaves them with few options.
    • Numerous worldwide health care developments are reshaping the PV function of today. While many of these changes offer significant advantages, they are also putting pressure on the safety measures now in place in biopharmaceutical businesses.
    • Many organizations are dealing with sizable financial burdens to maintain and upgrade these systems even though, according to the current safety system paradigm, the same trends may cause the costs of conventional upgrade approaches to increase at a rate that is out of proportion to the benefits. As a result, many biopharma companies are starting to think about how automation, cognitive technologies, and advanced analytics may help them get more out of their PV systems.
    • They are moving past the point where they are merely analyzing, formatting, and submitting patient reports and provider-supplied case processing and signaling data to the point where they are developing a next-generation digital learning system that effectively and affordably improves product quality and patient safety.

    Focus long term: Case assessment and reporting

    Case processing: With case volumes increasing gradually every year and PV budgets spending expenditure on case processing, bringing down costs is the top priority for survey participants. Low-cost leaders are outsourcing, utilizing scale, and accelerating the automation of case processing.

    Signaling: Most pharmaceutical companies still rely on established signal detection and investigation techniques. A small number are utilizing real-world evidence, and almost none are advancing social media channels. This is compatible with the capability of modern PV systems.

    Wide-ranging chances to increase signal processing and inquiry maturity are seen by survey respondents; half of them.

    Most respondents indicate they intend to increase their signal processing and investigation competence because they perceive the significant potential for improvement. Predictive signaling is the ultimate objective.

    Developing a next-generation PV system to increase patient safety

    Automation, cognitive technologies, and sophisticated analytics should all be included in PV budgets for biopharma businesses for the following reasons: decreasing case processing costs, enhancing signal processing capabilities, and speeding up product safety reports. But if biopharma uses digital technology to develop a subsequent-generation PV learning system for increased patient safety, we expect even greater advantages.

    A shift to a proactive, patient-centered strategy can make it possible to have a true, evidence-based center for safety intelligence throughout the whole product life cycle and to have a thorough understanding of product benefit-risk profiles.

    To process safety data, pharmaceutical companies currently use a few siloed information systems, which may hinder many of them from achieving the anticipated future state. For instance, different internal PV groups assess safety data obtained from external sources in diverse ways and for varied goals; each group may gather and analyze data from as many as a dozen different systems, leading, unsurprisingly, to the production of many versions of the truth.

    Implementing an end-to-end, modular “learning loop” system that uses a unified data platform and automation to cognitively process upstream and downstream safety information and leverage continuous learning to help mitigate risk, strengthen compliance, and improve patient outcomes is one way to break the case processing cost curve while also enhancing the role of signaling.

    Enhancing pharmacovigilance automation

    To ensure patient safety, all people concerned with drug development are accountable. Automation, smart technologies, and advanced analytics are opening possibilities for pharmacovigilance to change from the process of writing AE reports for regulators to creating a learning system that prioritizes benefit and risk management as well as proactive surveillance throughout the product life cycle.

    PV organizations should first consider their future goals and decide whether achieving them will require gradual or radical change.

    Sollers college offers short and long-term programs in Drug Safety and Pharmacovigilance. These job -oriented programs open a wide range of career opportunities in the pharmaceutical industry.

  • Discover the Key to Smart Pharmacovigilance

    Discover the Key to Smart Pharmacovigilance

    Today’s PV function has evolved into a corporate asset that boosts brand value and creates new growth opportunities because of various trends in global healthcare. However, maintaining the current safety systems is quite expensive.

    Pharmaceutical and biopharmaceutical businesses are under intense pressure to reduce case processing costs while maintaining high regulatory compliance and raising the safety profile of their products through proactive signal identification.

    Regulatory requirements force pharmaceutical and biopharma businesses to create a pharmacovigilance/drug safety surveillance program and keep an eye on the safety profiles of their marketed products during the whole product lifetime.

    To facilitate proactive identification and prediction of safety signals and benefit-risk evaluation for marketed medicines, businesses are increasingly focusing on reorganizing drug safety and risk management programs. These organizations are also combining data sets across all stakeholders (pharmaceutical companies, regulatory authorities, patients) to foster complete transparency, sharing, and partnership. 

    The industry processes and notifies local regulatory authorities of adverse occurrences using a variety of safety databases, such as Oracle Argus, ARIS-G, etc.

    Transformation to smart case processing is required

    1. The need for pharmaceutical companies to deploy and maintain more complex PV systems and manage safety surveillance activities is growing because of the changing regulatory environment and increased regulatory scrutiny, increasing disease complexity and the number of drugs getting approved, and growing awareness among patients and providers about reporting adverse events, social media connectivity resulting in a huge influx of data, and multiple templates or formats. 
    2. Given the shortage of safety talent compared to demand and the pressure on businesses to cut expenses associated with manual case processing because of the rising number of adverse occurrences, it is urgent to review the old manual methods of case processing. 

    Switching to adaptive case processing is required

    • The need for pharmaceutical companies to deploy and maintain more complex PV systems and manage safety surveillance activities is growing because of the changing regulatory environment and increased regulatory scrutiny, increasing disease complexity and the number of drugs getting approved, and growing awareness among patients and providers about reporting adverse events, social media connectivity resulting in a huge influx of data, and multiple templates or formats. 
    • Due to the lack of safety talent compared to demand and the pressure on businesses to reduce expenses associated with manual case processing because of the rising number of adverse occurrences, it is urgent to review the old manual methods of case processing.

    Case Processing Automation: Methods and Advantages

    • A typical roadmap for implementing an automation strategy would begin with process mapping and assessment to drive process improvements, make end-to-end case processing superior and leaner, and eliminate repetitive steps in existing processes.
    • Artificial intelligence technologies can be used to transform the way pharmacovigilance case processing is done, making it smarter at every stage with less need for human intervention. These technologies range from basic automation through robotic process automation to cognitive automation with natural language processing, and finally taking to machine learning. 
    • Although there are accessible cloud-based technologies, such as Oracle Argus, ARIS-G, etc., that automate case processing and reporting tasks, the process still necessitates a significant amount of manual labor during case intake and data entry. These operations are great candidates for automation utilizing RPA/AI technologies through the detection of patterns in unstructured data since they are rules-based, repeating, and generalized.
    • Automation of the entire process from case receipt to reporting can limit manual intervention to specific activities like handling exceptions, quality assurance, and medical review.
    • With the combined expertise of pharmacovigilance domain experts, data scientists, and IT engineers, standardization and automation strategies for PV processes have the potential to increase case process efficiency, leading to a significant cost reduction. They can also decrease manual errors, improve the quality of the deliverables, and guarantee regulatory compliance due to faster turnaround times. 
    • Through a clear vision, well-defined strategies, and implementation plans with mileposts to monitor progress at each stage and metrics to monitor effectiveness and benefits, the adoption of these novel technologies can therefore add a new level of speed and intelligence to the pharmacovigilance process.
    • Businesses that recognize the value of incorporating these cutting-edge disruptive technologies and utilizing them will fundamentally change the landscape of drug safety, be more effective in managing the increasing case volumes with better quality, and ultimately comply with the regulatory requirements related to the safety surveillance of their products.

    Create a pathway and learn in multiple ways and don’t hold yourself back. Optimize and reap your career right now!

  • Post-COVID-19 Pharmacovigilance Opportunities and Concerns

    Post-COVID-19 Pharmacovigilance Opportunities and Concerns

    Drug-related issues are dealt with pharmacovigilance (PV), which includes identifying, comprehending, and avoiding negative consequences. The main objective of PV is patient safety. The danger of side effects is present with many prescription medications.

    Doctors and researchers must be wary of any severe side effects, even if the benefits outweigh the risks. A successful PV system collects, assesses, and disseminates medication safety information to minimize patient risk as early as feasible. PV can affect both drugs that are approved and those that are still in clinical studies.

    Healthcare practitioners, public health specialists, and other professionals need accurate and recent safety information on drugs associated with COVID. PV is more essential than ever during the COVID-19 pandemic. Trials for COVID vaccinations and potential treatments are being carried out globally.

    Drug Safety

    The COVID-19 pandemic’s present issues have also led regulatory bodies to re-evaluate their standards and highlight the significance of electronic reporting to facilitate data interchange for patient safety. The support of local teams allows for prompt and proactive communication with established contacts at regulatory agencies to arrange alternative measures promptly, which is of the utmost importance during this period. 

    A dedicated safety intelligence team also enables an established communication channel with authorities.

    • Pandemic on a global scale

    The most critical aspects of drug research and regulation are because of COVID-19. The regulatory authorities and pharmaceutical companies are competing to discover a treatment for this deadly virus. 

    The growth of social distancing practices is quickly altering the conventions of the pharmaceutical sector, necessitating new procedures and techniques for conducting clinical studies.

    • COVID-19 pandemic lessons learnt to create a robust drug safety reporting system

    1. The significance of online reporting:

    This pandemic serves as a reminder of the superiority of electronic or paperless reporting.

    2. The significance of a strong and adaptable intelligence procedure

    For a sponsor to avoid interference with project activities, including fulfilling obligations for patient safety, access to current regulatory intelligence is essential. To guarantee compliance and quality, it can help to have a robust procedure for maintaining regulatory knowledge, a quick change-implementation process, and a reliable system for entering rule-based choices. 

    3. Established channels of contact with agencies

    In addition to ongoing monitoring of regulatory notifications, proactive engagement with agencies enables agencies, sponsors, and CROs to better comprehend one another’s needs and the difficulties they face.

    4. The automated submission oversight system

    A system that performs automated reporting assessment assists with generating and prioritizing tasks prepares submission packages, and can send communications to various teams for translation, courier, agency portal submission, or legal representative signature is essential for submission oversight. Automation significantly reduces human error in complex work environments during the pandemic.

    As time goes on, the stakeholders in the pharmacovigilance sector are putting more effort into effective regulation. Since healthcare practitioners are now making every effort to reduce the COVID-19 strain, remote reporting and data collection have been designed for increased efficiency and patient accessibility. Pharma employees are using the internet as a service to collect adverse effects remotely. Patients’ active participation in safety reporting on social media and company websites has signaled the seizing of a chance with enormous future potential.

    • Drug surveillance during COVID-19

    Considering the global health crisis, it is critical to monitor the safety of medications, vaccines, and medical devices. The stakeholders in pharmacovigilance and drug safety have been actively working towards monitoring their safety, while the healthcare businesses in every country are intent on developing effective vaccines. 

    However, due to pandemic-related operational disruptions, the pharmacovigilance sector has been dealing with ongoing difficulties in its operations. The pharmaceutical industry has been under pressure to develop COVID-19 medications and vaccines because of the unstable nature of the issue, which calls for clinical therapies.

    The pharmacovigilance industry oversees monitoring unknown short- and long-term adverse drug reactions, which are critical in determining the effects of drug and vaccine use. This is done to identify a solution quickly. Adopting a strong safety strategy and a long-lasting pharmacovigilance mechanism is, therefore, urgently necessary to meet the issues.

    Unfortunately, even essential work like pharmacovigilance has been affected by the pandemic. For example, numerous clinical trials have been halted or postponed due to local or national lockdowns, personnel quarantines, supply chain issues, and various other challenges.

    This intends to minimize the workload for overworked medical professionals and keep pharmaceutical business operations continuous.

    • Pharmaceutical Monitoring Beyond COVID-19

    PV has faced several difficulties because of COVID-19, though there are opportunities. Some pharmacovigilance experts believe this pandemic may help bridge the gap between pharmacovigilance and medical care.

    Physicians are frequently asked to make therapeutic choices during the COVID-19 crisis. The prompt analysis of this data will assist in giving professionals the direction they urgently require to keep their patients safe.

    It is also crucial for the PV community to share information. Resources can benefit from the assistance of well-funded PV teams. Data sharing could be beneficial for nations on the other side of the globe by enabling access to PV databases. Such partnerships may continue long after this pandemic has ended, potentially enhancing patient safety for millions of people.

    Honesty and transparency will be essential as the pandemic approaches its second year. Both a challenge and an opportunity exist for PV to identify and correct erroneous information as well as properly convey risk to both the public and healthcare professionals.

    • Innovative Projects for the Future

    The pharmacovigilance community has responded to the pandemic with speed. As a result, a solid knowledge base of risk-free illness therapies should be developed.

    The primary goal is to guarantee that patients receive the COVID-19 treatments and medical supplies they need as soon as feasible.

    Big data analytics is being used to combat COVID-19. This refers to the thorough study of data gathered from numerous sources. Professionals in pharmacovigilance will be able to exchange safety information in a productive and timely manner. A good illustration is the mandated usage of the ISO ICSR protocol for reporting specific instances of possible adverse effects. The substance, product, organization, and referential (SPOR) data master data domains are the four domains of master data used in pharmaceutical regulatory processes and the ISO IDMP standards.

    Pharmacovigilance will also continue to attract more patient interest. By actively involving patients in decision-making, our healthcare system will become more and more participatory. The pharmacovigilance system will undoubtedly change as patients become more proactive, making it even more patient-centric. Finally, the WHO has created collaborating centers designed to promote PV worldwide. These centers are responsible for Drug Monitoring, Statistics and Methodology, PV Advocacy and Training, PV Practices Strengthening, PV in Education and Patient Reporting, and PV in Practices. 

    Are you looking for support? Sollers College is ready to help you find the best career in a PV career.

  • Strengthen your Pharmacovigilance Career with a Master’s Degree

    Strengthen your Pharmacovigilance Career with a Master’s Degree

    Through new developments, pharmacovigilance has developed into a vigilant system to check on the security of medications. There is a good demand for qualified professionals in pharmacovigilance, and regulatory agencies. Pharmacovigilance, therefore, has become the prime focus in the healthcare industry to ensure that the right products reach the patients at the right time with optimized benefits and risks.

    The Master’s degree program in pharmacovigilance is aimed at generating qualified and competent Pharmacovigilance professionals who can operate effectively at different levels in Pharmacovigilance departments of prominent Pharma firms and Clinical Research Organizations worldwide. Master of Science in Pharmacovigilance Regulations focuses on pharmacovigilance, allowing MD graduates to pursue positions as project managers, drug administrators, and safety directors in the global marketplace.

    The curriculum is designed for grooming health care professionals with a strong background in fields like medicine, pharmacy, dentistry, nursing, biostatistics, and information technology, who are willing to shift their gear towards the pharma industry and for students who seek to expand their knowledge of pharmacovigilance and drug safety. Our master’ Program is structured to equip individuals with the knowledge and skills needed for employment and career advancement.

    This master’s program provides a foundation in pharmacovigilance principles to experienced professionals and those seeking to enter this career field from both within and outside the pharmaceutical industry. An accredited postgraduate program developed by our team in pharmacovigilance help students reaches their goals. Learn from leading pharmacovigilance training providers and earn an industry-recognized qualification in a flexible format that fits work and lifestyle.

    This international master’s program provides specializations to meet professional needs in medical benefit assessment, medicine risk identification and quantification, medicine benefit-risk assessment, medicine, and public health, and medicine risk communication.

    Career scope in various fields after masters

    Courses in Pharmacovigilance 

    One can enroll in a pharmacovigilance-related certificate or diploma program after graduating. For those who are interested, there are numerous certificate programs accessible. The period varies from course to course, however.

    Job Opportunities in Pharmacovigilance

    There won’t be a lack of employment in this industry. Along with a few roles in the public sector, prominent pharmaceutical corporations provide numerous job options to candidates.

    Job Responsibilities in Pharmacovigilance

    Tracking all drug-related reports is one of the functions and duties of a pharmacovigilance specialist. They must examine and evaluate each drug-related material.

    Pharmacovigilance Jobs

    • Safety Compliance Writer
    • Good PV Practices manager
    • GCP specialist
    • Pharmacovigilance vendor
    • Case processing specialist
    • Clinical trial case processing safety specialist
    • Post-marketing case processing safety specialist
    • Epidemiology safety associate

    Pay for Pharmacovigilance

    One can begin a job in this field with a competitive annual salary after completing a pharmacovigilance certificate or diploma program. It will naturally increase over a few years. For knowledgeable and skilled individuals, though, the possibilities are endless.

    Want to learn more about the subject but are just getting started?

    Sollers College Masters PV Program is extremely competent.

    Students can start this program today and take the first step toward a career that will change their lives now!

  • Pharmacovigilance_ The Next Booming Career Option

    Pharmacovigilance_ The Next Booming Career Option

    The global coronavirus pandemic has resulted in many fatalities, making pharmaceutical safety reporting and monitoring critical in the context of potential therapeutic regimens. Pharma businesses outsource the pharmacovigilance process to reduce fixed overhead costs and large upfront investments, gain additional capacity, and boost resource flexibility. 

    For small and medium-sized businesses, outsourcing pharmacovigilance is a cost-effective option. The greater awareness of pharmacovigilance’s significance, the investigation and marketing of a broader range of pharmaceutical products, and more strict and detailed regulatory criteria have all contributed to this growth. The pharmacovigilance and drug safety market are growing as a result of such advances among pharma firms.

    The primary purpose of pharmacovigilance is to enable the use of drugs in a safer way. However, it is under increasing pressure to analyze more data more quickly, monitor hazards more extensively, and accurately report worldwide patient events. 

    What is Pharmacovigilance?

    Pharmacovigilance (PV) entails tasks such as monitoring, detecting, and preventing adverse effects or other drug-related issues. 

    It is a continual process that includes actions to improve the safe use of medicines while also evaluating their safety. Pharmaceutical businesses are thought to have the biggest market share in the pharmacovigilance end-user segment.

    Pharmacovigilance (PV) data is crucial in identifying viable treatment options for COVID-19 and finding a means to minimize or reduce morbidity and mortality. The influx of clinical and PV data includes new therapeutic information for COVID-19 treatment as well as possible drug interactions to consider.

    Pharmacovigilance databases can be utilized for a wide range of observational research and contain numerous real examples, making them a valuable source of data. It primarily focuses on reporting and assessing pharmacological adverse effects, as well as assuring that drugs are safe and secure.

    The use of correct analytics is critical, yet firms often prioritize data processing over analysis, resulting in sub-optimal results. Integrating intelligent technologies all the way through the value chain can be beneficial. 

    Are you eager to expand your professional horizons?

    Don’t worry, we’re here at Sollers to assist you and satisfy your preferences with scientific understanding. At Sollers, you can learn, train, and take courses to expand your expertise. Without a doubt, learning new skills and learning about drug safety and pharmacovigilance is a simple process.

    So, what are you awaiting?

    Join Sollers to gain professional pharmacovigilance and drug safety training and expand your knowledge. You can rely on us for in-depth training in this competitive area, whether you are a recent college graduate or a working professional. 

    Use our global experience and tried-and-true technology to keep yourself safe from the start. Companies will concentrate on simplifying and reducing costs in the next years.

    Throughout the compliance paradigm, our comprehensive methodology delivers the next generation with focused value-creation areas you’ve never seen before.

    To sum up, pharmacovigilance innovation is never-ending. With new advances in pharmacovigilance, there will be numerous advanced technology solutions in the future.

  • How to Launch Your Career in Clinical Research?

    How to Launch Your Career in Clinical Research?

    CRAs who wish to advance their careers might wonder where to begin if they have some experience in clinical research. There may be a possibility of speeding your job up for ambitious and dedicated CRAs.

    You can advance your career in clinical research in three ways.

    Get benefits from CRO training programs

    When seeking a new position at a large clinical research organization (CRO) or seeking on-the-job training, don’t overlook these opportunities for career advancement. While many CROs provide mandatory training to their CRAs, additional, optional courses can help promote activity.

    Sollers is one of the prominent colleges in the US. It is committed to CRA career development and provides education and training through its learning platform. 

    This form of self-directed professional development can help you advance clinical research to more senior positions.

    Talking to someone who has already risen to a more senior position as a CRA is one of the most excellent methods to determine how to take the next step in your career as a CRA. It will be a project manager or line manager who has worked as a CRA before in most circumstances.

    Look for a Mentor

    A mentor may be a great resource in assisting you in realizing your professional development objectives and laying out the measures required to attain them. They may frequently propose particular areas where you should focus your efforts to develop new information and abilities and alert you to upcoming advancement chances.

    Mentors may also help you manage your short- and long-term career goals for planned career paths as clinical research specialists.

    Clinical researchers come from a variety of professions, including nursing and pharmacology. By understanding what your prior responsibilities assist you to contribute to your career as a CRA, you may celebrate and use your unique experience.

    It may have been your previous experience volunteering in hospitals that sparked your interest in clinical research. If you served as a clinical research coordinator (CRC) at a site, you may have seen how crucial organisation is to managing patients and supporting the trial.

    Utilize Your Unique Experience

    Regardless of what you performed before becoming a CRA, your previous experiences will undoubtedly influence how you approach clinical research. 

    As CRAs develop in their careers, those who can appreciate the significance of their particular history will have a more significant opportunity of applying those lessons to their present and future jobs.

    Contact us to understand how managers at a top CRO recognize high-potential professionals if you’re eager to advance your career as a CRA.

  • How Data Science Plays a Role in the Pharma Industry?

    How Data Science Plays a Role in the Pharma Industry?

    Data science has proven extremely useful for extracting actionable insights from data in the current healthcare market.  Health institutes generate vast amounts of data when serving prominent people in our modern era. Electronic medical records, CRM databases, clinical trial databases, billing, wearable devices, and scientific articles generate so much data every 10 seconds that they are impossible to process without advanced technologies and cutting-edge techniques. 

    Today’s healthcare industry finds excellent use of data science, a field of study that focuses on extracting meaningful insights from data. 

    Big Data and Machine Learning in Data Science 

    Healthcare has become more data-driven thanks to Big Data and Machine Learning. It is mainly due to new intelligent software devices and solutions that improve healthcare services that healthcare data growth is accelerating. 

    Data Science Applications In Healthcare:

    Medical Image Analytics 

    Data Science is revolutionising the field of image analytics. Analysing medical images can identify even the tiniest microscopic defects. Industries that generate ideas on a large scale can significantly benefit from image analytics. 

    With the advent of deep learning techniques in Data Science, software programs can learn to understand and interpret X-rays, mammographies, MRIs, etc. 

    Using the software, bacteria detection is automated, making it more efficient. The program recognizes bacteria stamps and differentiates them into three classes based on the provided and processed datasets. As a result, MicroTechnix enhances the speed and efficiency of bacteria identification processes, avoiding human errors as the software is fully automated and does not need supervision. 

    Quantified Health 

    Quantified Health is a relatively new concept, which refers to the processing and analysis of data directly from consumer wearable devices. People continuously create a large set of health data with the ever-increasing ownership of wearables, apps, and sensors that track heartbeat, temperature, sleep and step patterns, water consumption, or mood states. 

    Cutting-edge technologies based on Data Science techniques and methods can help analyze  provided data in real-time, detecting any deviations from the prescribed norms and reporting them to the users and their attending physicians.

    Data Science for Post-care Monitoring 

    Any surgery or complex treatment comes with the risk of complications. Once the patient leaves the hospital and is no longer under constant medical supervision, it becomes difficult to detect any anomalies or deviations in their condition in case they occur.

    Predictive Diagnosis and Disease Prevention 

    Data-powered predictive systems use historical data, learn from them, identify patterns, and make accurate predictions.Tracking devices make it possible to detect a problem before it gets out of hand. The system identifies various symptoms, recognizes habits and risks of diseases, and creates meaningful predictions. 

    Data Science For Drug Discovery 

    Drug discovery is a costly and time-consuming process. According to a Pharma report, the average cost of successful drug development is estimated to be $2.6 billion, and it takes at least ten years to create an efficient drug and bring it to the market. Moreover, data science algorithms can simulate how the drug will act in the human body without long laboratory research. 

    NLP for Electronic Health Records

    Electronic Health Records (EHRs) are medical data stored in digital format. Using the Natural Language Processing (NLP) technology, which can process and understand natural language, old unstructured hand-written records can be kept in electronic healthcare systems. 

    NLP-powered systems can process unstructured data, analyze the grammatical structure, determine the meaning of the data and summarize the information. 

    Biometrics in Healthcare 

    Based on Computer Vision technology, Biometrics software scans particular body parts and matches them with available patterns. 

    For instance, they reach a patient’s face to a previous biometric sample. Mostly, hospitals use biometrics systems for patient identification at check-in to promptly access patient documents and records. 

    By 2025, the market for healthcare biometrics is expected to reach $14.5 billion, according to Grand View Research. 

    With the proliferation of Data Science and the emergence of numerous data-powered applications, the Healthcare industry stays at the forefront. It actively implements data-driven solutions to provide its clients with a better lifestyle and personalized services.  A certification program in Data Science can help to settle in your career. 

  • Ways to Boost Patient Experience in Clinical Trials

    Ways to Boost Patient Experience in Clinical Trials

    A decade ago, the life sciences sector was junctured to improve patient trust and clinical trial results. Companies have realized that patients and advocates need to sit at the table and center on enterprise models, commercialization, and research and development. It’s a lofty goal to collect as many data points as possible in the shortest amount of time feasible. And how can we recognize the impact that taking part in a clinical study has on the patients we are attempting to help in this way?

    Patients Should Be Walked Through The Clinical Process Frequently And Early

    In most clinical trials, participants don’t think about the additional treatments they’ll be subjected to while selecting whether or not to take part. Is it worth missing several weeks of your life to have therapy that is only available in a few select places? 

    During Study Design, Consider the Patient’s Perspective

    It is very accurate when it comes to creating a positive patient experience. It’s essential to consider the study’s overall goal while deciding what procedures should be included in the protocol, even if many minor details are involved. Even if a surgery isn’t too taxing on its own, the cumulative toll on the patient can be staggering.

    Solicit Patient Input On Your Study Protocol

    Some patients consider clinical trials to help themselves and, more importantly, to help others in the future. As healthcare community members, we can’t take advantage of that desperation. Sponsors must consider the patient a partner in research and the end of their product. In the absence of this step, sponsors risk having a trial that can’t be conducted correctly and, unfortunately, won’t gather the data needed for the proposed study. Our focus must always be on the patients, the driving force behind continuous improvement in the healthcare industry.

    Using technology to reduce the patient burden

    Life sciences companies have to examine their current practices in light of the year 2020’s events and determine how to meet patients’ needs better while also prioritizing patient safety while planning clinical trials. To save their studies, several sponsors have scoured their networks and relationships for methods to collect clinical trial data from problems that are still in progress. It was when technology stepped in.

    When conducting clinical trials remotely or with minimal in-person visits, a clinical trial becomes more patient-centered by design. Clinical investigators and site staff can communicate by teleconference, reducing travel stress on the patient and allowing for a more flexible visit schedule.

    Both researchers and patients benefit from clinical studies. Because these studies are critical, it’s natural to focus on how effective the therapies are when considering their significance. Patients’ experiences in clinical studies are just as meaningful; however, As a patient, what are clinical trials like, and how can healthcare practitioners enhance their experience? Enroll in our certificate program for Clinical Trial Management today. This program is designed to meet the needs of the industrial market.

×